<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<page>

<p align="center"><font size="2" face="serif">SECURITIES AND EXCHANGE COMMISSION<br>WASHINGTON, D.C. 20549</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td><hr align="center" size="1" noshade width="15%"></td> </tr>
</table>
<p align="center"><font size="2" face="serif">FORM 8-K</font></p>
<p align="center"><font size="2" face="serif">CURRENT REPORT<br>PURSUANT TO SECTION 13 OR 15(d) OF<br>THE SECURITIES EXCHANGE ACT OF 1934</font></p>
<p align="center"><font size="2" face="serif">Date of Report (Date of earliest event reported):  May 11, 2006</font></p>
<p align="center"><font size="2" face="serif"><u>Savient Pharmaceuticals, Inc.</u></font><br>
<font size="2" face="serif">(Exact name of registrant as specified in charter)</font></p>
<table width="100%" border="0" align="center" cellpadding="0" cellspacing="0">
<tr valign="bottom" bgcolor="#ffffff">
<td width="33%" align="center"><font size="2" face="serif"><u>Delaware</u></font></td>
<td align="center"><font size="2" face="serif"><u>0-15313</u></font></td>
<td width="33%" align="center"><font size="2" face="serif"><u>13-3033811</u></font></td>
</tr>
<tr valign="bottom" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">(State or other juris-<br>diction of incorporation</font></td>
<td align="center"><font size="2" face="serif">(Commission<br>File Number)</font></td>
<td align="center"><font size="2" face="serif">(IRS Employer<br>Identification No.)</font></td>
</tr>
</table>
<br>
<p align="center"><font size="2" face="serif">One Tower Center, 14th Floor</font><br>
<font size="2" face="serif"><u>East Brunswick, New Jersey 08816</u></font><br>
<font size="2" face="serif">(Address of principal executive offices) (Zip Code)</font></p>

<p align="center"><font size="2" face="serif">Registrant&#146;s telephone number, including area code:  (732) 418-9300</font></p>
<p align="center"><font size="2" face="serif"><u>Not applicable</u></font><br>
<font size="2" face="serif">(Former name or former address, if changed since last report)</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif"><img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif"><img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif"><img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif"><img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td>
</tr>
</table>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p2"></a>
<p align="left"><font size="2" face="serif"><b>Item 2.02.  Results of Operations and Financial Condition</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On May 11, 2006, Savient Pharmaceuticals, Inc. (the &#147;Registrant&#148;) announced its financial results for the quarter and fiscal year ended March 31, 2006.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, on May 11, 2006, the Registrant held a publicly available live webcast discussion of its financial results for the quarter ended March 31, 2006.  The transcript of the May 11, 2006 conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 9.01.  Financial Statements and Exhibits</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">See Exhibit Index attached hereto.</font></td>
</tr>
</table>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p3"></a>
<p align="center"><font size="2" face="serif">SIGNATURE</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>

<table width="100%" cellspacing="0" cellpadding="0" border="0">
</table>

<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="bottom">
  <td width="50%" align="left">&nbsp;</td>
  <td width="3%" align="left">&nbsp;</td>
  <td colspan="2" align="left"><font size="2" face="serif">SAVIENT PHARMACEUTICALS, INC.</font></td>
  </tr>
<tr valign="bottom">
  <td width="50%" align="left"><font size="2" face="serif">Date: May 12, 2006</font></td>
  <td width="3%" align="left">&nbsp;</td>
  <td width="3%" align="left"><font size="2" face="serif">By:</font></td>
  <td align="left"><font size="2" face="serif">/s/ Philip K. Yachmetz</font></td>
</tr>
<tr valign="bottom">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left"><hr align="center" size="1" noshade>
    </td>
</tr>
<tr valign="bottom">
<td width="50%" align="left"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%" align="left">&nbsp;</td>
<td width="3%" align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Philip K. Yachmetz<br>Executive Vice President &amp; <br>Chief Business Officer</font></td>
</tr>
</table>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p4"></a>
<p align="center"><font size="2" face="serif">EXHIBIT INDEX</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" bgcolor="#FFFFFF">
<td align="left" valign="bottom"><font size="2" face="serif"><u>Exhibit No.</u></font></td>
<td width="2%" align="left" valign="bottom">&nbsp;</td>
<td width="59%" align="left" valign="bottom"><font size="2" face="serif"><u>Description</u></font></td>
</tr>
<tr valign="top">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left" valign="bottom"><font size="2" face="serif">99.1</font></td>
<td align="left" valign="bottom">&nbsp;</td>
<td align="left" valign="bottom"><font size="2" face="serif">Press release dated May 11,  2006</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
  <td align="left" valign="bottom">&nbsp;</td>
  <td align="left" valign="bottom">&nbsp;</td>
  <td align="left" valign="bottom">&nbsp;</td>
  </tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left" valign="bottom"><font size="2" face="serif">99.2</font></td>
<td align="left" valign="bottom">&nbsp;</td>
<td align="left" valign="bottom"><font size="2" face="serif">Transcript dated May 11, 2006</font></td>
</tr>
</table>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b413241_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 8474}]
{"company-data": {"conformed-name": "SAVIENT PHARMACEUTICALS INC", "cik": "0000722104", "assigned-sic": "2833", "irs-number": "133033811", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-15313", "film-number": "06835722"}, "business-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816", "phone": "7324189300"}, "mail-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816"}, "former-company": {"former-conformed-name": "BIO TECHNOLOGY GENERAL CORP", "date-changed": "19920703"}}
Prepared and filed by St Ives Financial
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):  May 11, 2006
Savient Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
Delaware
0-15313
13-3033811
(State or other juris-
diction of incorporation
(Commission
File Number)
(IRS Employer
Identification No.)
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:  (732) 418-9300
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02.  Results of Operations and Financial Condition
On May 11, 2006, Savient Pharmaceuticals, Inc. (the "Registrant") announced its financial results for the quarter and fiscal year ended March 31, 2006.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In addition, on May 11, 2006, the Registrant held a publicly available live webcast discussion of its financial results for the quarter ended March 31, 2006.  The transcript of the May 11, 2006 conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
Item 9.01.  Financial Statements and Exhibits
(d)      Exhibits
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SAVIENT PHARMACEUTICALS, INC.
Date: May 12, 2006
By:
/s/ Philip K. Yachmetz
Philip K. Yachmetz
Executive Vice President &
Chief Business Officer
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press release dated May 11,  2006
99.2
Transcript dated May 11, 2006